22 July 2024
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Conversion Notice and Total
Voting Rights
SkinBioTherapeutics plc, (AIM: SBTX,
or the "Company"), the life science business focused on skin
health, announces that it received a Conversion Notice on 17 July
2024 from Macquarie ("Macquarie") for £160,000 of Convertible Bonds
from the £5.0 million convertible bond facility announced on 25
January 2024. The Company has drawn a total of £1,600,000 under the
Facility. Following this conversion, the balance of ourstanding
bonds will be £480,000.
SkinBioTherapeutics will issue
1,989,879 ordinary shares of £0.01 per share ("Ordinary Shares") at
a conversion price of 8.040687p per Ordinary Share.
Admission and Total Voting Rights
Application has been made for
the 1,989,879 new ordinary shares, which will rank pari
passu in all respects with the existing ordinary shares of the
Company, to be admitted to AIM, which is expected to occur on or
around 8.00 a.m. on 24 July 2024 ("Admission"). Upon Admission, the
total number of issued shares and the total number of voting rights
in the Company will be 205,361,916.
The above figure of 205,361,916
should be used by shareholders in the Company as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the share capital of the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
-Ends-
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
For
more information please contact:
|
SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Manprit Randhawa, CFO
|
Tel:
+44 (0) 191 495 7325
|
|
Cavendish Capital Markets Limited
(Nominated Adviser & Broker)
Giles Balleny, Dan Hodkinson
(Corporate Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith
(Sales)
|
Tel:
+44 (0) 20 7220 0500
|
|
Instinctif Partners (financial press)
Melanie Toyne-Sewell / Jack
Kincade
|
Tel:
+44 (0) 20 7457 2020
SkinBioTherapeutics@instinctif.com
|
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life
science company focused on skin health. The Company's proprietary
platform technology, SkinBiotix®, is based upon
discoveries made by the translational dermatology team at the
University of Manchester.
The Company is targeting a number of
skin healthcare sectors, the most advanced of which are cosmetic
skincare and food supplements to modulate the immune system by
harnessing the gut-skin axis. In each area SkinBioTherapeutics
plans to exemplify its technology through human studies. The
Company's first product, AxisBiotix-Ps™, a food supplement to
address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April
2017 and is based in Newcastle, UK. For more information,
visit: www.skinbiotherapeutics.com
and www.axisbiotix.com.